GlassScriptPhysician profile
Kathy Mayo
NPI 1548372949
$13,733.11
in general payments reported to CMS, 2019-2025
32 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,436 · 2020: $1,380 · 2021: $2,150 · 2022: $2,206 · 2023: $2,702 · 2024: $1,736 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,456 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,455.60 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,991.90 | 2021-2025 | |
| Allergan, INC. | $1,316.27 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $988.97 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $939.43 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $851.68 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $845.67 | 2020-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $635.62 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $537.98 | 2021-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $447.09 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $439.90 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $423.93 | 2020-2023 | Trintellix |
| Axsome Therapeutics, INC. | $413.80 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $373.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $322.23 | 2019-2023 | Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $295.62 | 2019-2023 | Belsomra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $280.75 | 2020-2022 | |
| Corium, LLC | $279.92 | 2022-2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $258.68 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $237.88 | 2020-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $214.11 | 2019-2023 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $199.95 | 2019-2022 | |
| Adlon Therapeutics L.P. | $107.52 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $54.45 | 2022 | |
| Shire North American Group INC | $43.08 | 2019 | |
| Almatica Pharma LLC | $40.88 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Brainsway USA INC | $39.13 | 2023-2025 | Deep Tms System |
| Tris Pharma INC | $37.62 | 2025 | Dyanavel Xr |
| Owp Pharmaceuticals, INC. | $35.69 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $30.53 | 2022-2023 | Nuplazid |
| Biogen, INC. | $22.51 | 2024 | |
| Neuronetics, INC. | $17.77 | 2020 | |
| Currax Pharmaceuticals LLC | $8.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Mayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.